Loading...
Market
What will be the next major milestone announcement for VK2735 by November 2025?
2
Resolution / Starting Odds
Phase 2 trial results • 25%
Partnership announcement • 25%
Regulatory submission • 25%
Other milestone • 25%
Official announcements from Viking Therapeutics
Story
Viking Therapeutics' Obesity Drug Shows 8.2% Weight Loss, Strong Safety Profile
Nov 4, 2024, 01:44 AM
Viking Therapeutics ($VKTX) has reported promising results from its Phase 1 trial of the oral obesity drug VK2735. The drug demonstrated an 8.2% weight loss in patients, positioning it as a strong competitor against market leaders like Novo Nordisk ($NVO) and Eli Lilly ($LLY). The trial also highlighted the drug's excellent safety profile, showing similar gastrointestinal tolerability to placebo across all dose escalations up to 100mg. The study observed no moderate or severe nausea and only one case of vomiting, even at higher doses. Additionally, a 28-day study showed a 5.3% reduction from baseline with no discontinuations. These results have generated significant anticipation in the market, with analysts suggesting that VK2735 could potentially reach triple-digit stock prices. The total addressable market (TAM) for obesity treatments is estimated to be over $200 billion, while Viking Therapeutics' market cap is currently around $10 billion.
View original story
Similar markets
Positive efficacy and safety • 25%
Positive efficacy, negative safety • 25%
Negative efficacy • 25%
Inconclusive • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Phase 1 completion • 25%
Phase 2 initiation • 25%
Partnership announcement • 25%
Other milestone • 25%
Granted in 2024 • 25%
Granted in 2025 • 25%
Not granted by 2025 • 25%
Other designation received • 25%
Phase 2 Clinical Trial Approval • 25%
Breakthrough Therapy Designation • 25%
Priority Review Designation • 25%
Other • 25%
VK2735 leads market • 25%
VK2735 is second • 25%
VK2735 is third • 25%
VK2735 has negligible share • 25%
Initiation of Phase 4 trial • 25%
Regulatory approval in Europe • 25%
Launch of a new indication study • 25%
No major milestone announced • 25%
Successful autonomous navigation in open waters • 25%
Integration with U.S. Navy's existing systems • 25%
Completion of first production-ready ASV • 25%
Other • 25%
Progress to Phase 2 • 25%
Significant efficacy results • 25%
Safety concerns emerge • 25%
No significant milestone • 25%
